ACON Investments Completes Sale of Vitalis
- Editor
- Feb 6
- 1 min read
What's Happening: ACON Investments has sold its stake in Vitalis S.A.C.I., a Colombian manufacturer of injectable pharmaceuticals, to Laboratorios Sanfer, a major Mexican pharmaceutical company. This exit comes after ACON's acquisition of Vitalis in 2021, during which time the company experienced significant growth and expansion across Latin America.
The Key Moves:
Vitalis expanded its manufacturing capacity and upgraded facilities to meet high quality standards.
The company broadened its product portfolio to over 700 registered products.
Vitalis strengthened its geographic footprint, including an acquisition in Chile.
By The Numbers :
ACON has invested in 44 companies across 10 different countries in Latin America over 29 years.
30 of ACON's Latin American investments have been sold to strategic or financial buyers.
ACON has managed $7.2 billion in assets since inception.
Key Quotes:
"This has been a very successful investment for us and exemplifies ACON's disciplined, value-driven strategy and our ability to deliver strong performance despite dynamic market conditions," said Alberto Hernández, Partner at ACON Investments.
"Our collaboration with Vitalis showcases ACON's ability to grow businesses across Latin America while working alongside management teams to drive sustainable growth, foster innovation and create lasting social and environmental impact."
*KQ3*
The Bottom Line: ACON Investments' successful exit from Vitalis demonstrates the fund's ability to create value in Latin American markets. The sale follows recent exits from Brazilian companies and reinforces ACON's track record of growing businesses in the region while focusing on sustainable growth and innovation.
コメント